23andMe Holding Co. Chief Executive Officer Anne Wojcicki is considering splitting the DNA testing company’s consumer and therapeutics businesses in an effort to revive a sagging stock price and avoid being delisted.

“We’re exploring different opportunities,” she said in an interview this week from the company’s headquarters in Sunnyvale, California. 23andMe’s shares have traded below the $1 Nasdaq minimum since late last year, and the clock is ticking to regain complianceBloomberg Terminal.

ncG1vNJzZmivp6x7o7jOqKSbnaKce6S7zGilnq%2BjZK6zwMico56rX2d9c4CMaWlmaGdkf3StzZ2knmWTmrxusdepo6iqlah6tLzLoqutoZ6ceqW6wGaaqKWglru6ecinZK2vnw%3D%3D